Mary J Thomson, Marina Serper, Vandana Khungar, L Michael Weiss, Huy Trinh, Roberto Firpi-Morell, Michael Roden, Rohit Loomba, A Sidney Barritt, Derek Gazis, Andrea R Mospan, Michael W Fried, K Rajender Reddy, Anna S Lok
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1 Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,2 and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.3 , 4 Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity...
February 2022: Clinical Gastroenterology and Hepatology